Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333980 | 1.00 | CYP11B2 (0.58) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL12093056 | 1.00 | CYP11B2 (0.58) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Hydrochloric Acid SCHEMBL12077419 | 0.98 | CYP11B2 (0.56) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL2083702 | 0.93 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL12533763 | 0.82 | CYP11B2 (0.67) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL12533764 | 0.82 | CYP11B2 (0.67) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL12533767 | 0.82 | CYP11B2 (0.67) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL12533759 | 0.82 | CYP11B2 (0.67) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL1334683 | 0.79 | — | — | |
| SCHEMBL1334685 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350068-B1 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2350068-B1 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-8829027-B2 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8829027-B2 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8829027-B2 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8609690-B2 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | HSD11B1, HSD11B2, HSD17B1 | CYP11B2 10/4885CHRNB2 2684/4885CHRNA4 3637/4885 |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | HSD11B1, HSD3B1, HSD11B2 | CYP11B2 20/4885CHRNB2 2806/4885CHRNA4 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.